Jay Pepose - Jan 10, 2023 Form 4 Insider Report for Ocuphire Pharma, Inc. (OCUP)

Role
Director
Signature
/s/ Emily J. Johns, by Power of Attorney
Stock symbol
OCUP
Transactions as of
Jan 10, 2023
Transactions value $
$0
Form type
4
Date filed
1/12/2023, 04:34 PM
Previous filing
Jul 6, 2022
Next filing
Apr 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUP Common Stock Award +13K +39.56% 45.9K Jan 11, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUP Stock Option (right to buy) Award $0 +33.3K $0.00 33.3K Jan 10, 2023 Common Stock 33.3K $3.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted shares of common stock in lieu of cash for board services for 2023. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $3.07 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to January 11, 2023.
F2 The option will vest with respect to 8,322 shares on January 10, 2024, with the balance vesting quarterly in twelve equal installments thereafter.